Novo

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

by
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value. The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company’s ambitions for a successor to its Wegovy weight-loss drug that is more powerful than … Read more

Novo weight-loss drug Wegovy shows heart benefit in trial

by
Novo weight-loss drug Wegovy shows heart benefit in trial

Novo Nordisk said on Tuesday a large study had shown its highly effective obesity drug Wegovy also had a clear cardiovascular benefit, boosting the Danish drugmaker’s hopes of moving beyond Wegovy’s image as a lifestyle drug. The late-stage trial showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death … Read more